EU approves skin cancer fighting drug: Roche

Swiss drug giant Roche said on Monday it had been given European Union approval for its treatment to fight a highly aggressive form of skin cancer.

The European Commission gave the green light to Zelboraf, a drug used to treat adults with BRAF V600 mutation-positive unresectable or , the company announced in a statement.

If diagnosed early is generally curable but when it spreads to other parts of the body it is the deadliest form of .

Currently only one in four people lives for more than a year following diagnosis.

US approved Zelboraf in August last year, with Roche describing initial sales as "very encouraging."

The group recorded Zelboraf sales worth 31 million Swiss francs (25.7 million euros) in 2011.

The treatment, already approved by Switzerland, Brazil and Canada among others, has "revolutionised melanoma treatment," said analysts at the Zurich Cantonal Bank (ZKB).

Roche said the drug allows people to live significantly longer, with trials showing the risk of death was reduced by 63 percent for people who received Zelboraf compared to those who received standard first-line treatment.


Explore further

US approves new drug against skin cancer

(c) 2012 AFP

Citation: EU approves skin cancer fighting drug: Roche (2012, February 20) retrieved 24 October 2021 from https://medicalxpress.com/news/2012-02-eu-skin-cancer-drug-roche.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors